These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 32376390

  • 1. MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.
    Rice S, Roy A.
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194564. PubMed ID: 32376390
    [Abstract] [Full Text] [Related]

  • 2. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ, Schneider P, Pieters R, Stam RW.
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [Abstract] [Full Text] [Related]

  • 3. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
    Stumpel DJ, Schotte D, Lange-Turenhout EA, Schneider P, Seslija L, de Menezes RX, Marquez VE, Pieters R, den Boer ML, Stam RW.
    Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
    Schafer E, Irizarry R, Negi S, McIntyre E, Small D, Figueroa ME, Melnick A, Brown P.
    Blood; 2010 Jun 10; 115(23):4798-809. PubMed ID: 20215641
    [Abstract] [Full Text] [Related]

  • 6. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW, den Boer ML, Passier MM, Janka-Schaub GE, Sallan SE, Armstrong SA, Pieters R.
    Leukemia; 2006 Feb 10; 20(2):264-71. PubMed ID: 16357833
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
    Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW.
    Blood; 2009 Dec 24; 114(27):5490-8. PubMed ID: 19855078
    [Abstract] [Full Text] [Related]

  • 9. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R.
    Blood; 2010 Feb 04; 115(5):1018-25. PubMed ID: 19965632
    [Abstract] [Full Text] [Related]

  • 10. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
    Rice S, Jackson T, Crump NT, Fordham N, Elliott N, O'Byrne S, Fanego MDML, Addy D, Crabb T, Dryden C, Inglott S, Ladon D, Wright G, Bartram J, Ancliff P, Mead AJ, Halsey C, Roberts I, Milne TA, Roy A.
    Nat Commun; 2021 Nov 25; 12(1):6905. PubMed ID: 34824279
    [Abstract] [Full Text] [Related]

  • 11. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
    Fang K, Han BW, Chen ZH, Lin KY, Zeng CW, Li XJ, Li JH, Luo XQ, Chen YQ.
    Hum Mol Genet; 2014 Jun 15; 23(12):3278-88. PubMed ID: 24488769
    [Abstract] [Full Text] [Related]

  • 12. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
    Sison EA, Rau RE, McIntyre E, Li L, Small D, Brown P.
    Br J Haematol; 2013 Mar 15; 160(6):785-97. PubMed ID: 23294096
    [Abstract] [Full Text] [Related]

  • 13. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ, Schneider P, van Roon EH, Pieters R, Stam RW.
    Eur J Cancer; 2013 Jan 15; 49(1):175-84. PubMed ID: 22921182
    [Abstract] [Full Text] [Related]

  • 14. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M, Driessen EM, Willekes M, Pinhanços SS, Schneider P, Pieters R, Stam RW.
    Oncotarget; 2017 Feb 28; 8(9):14835-14846. PubMed ID: 27588400
    [Abstract] [Full Text] [Related]

  • 15. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Garrido Castro P, van Roon EHJ, Pinhanços SS, Trentin L, Schneider P, Kerstjens M, Te Kronnie G, Heidenreich O, Pieters R, Stam RW.
    Leukemia; 2018 Feb 28; 32(2):323-331. PubMed ID: 28690313
    [Abstract] [Full Text] [Related]

  • 16. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
    Yang L, Ding L, Liang J, Chen J, Tang Y, Xue H, Gu L, Shen S, Li B, Chen J.
    Pediatr Blood Cancer; 2018 Oct 28; 65(10):e27266. PubMed ID: 29943896
    [Abstract] [Full Text] [Related]

  • 17. The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia.
    Emerenciano M, Meyer C, Mansur MB, Marschalek R, Pombo-de-Oliveira MS, Brazilian Collaborative Study Group of Infant Acute Leukaemia.
    Br J Haematol; 2013 Apr 28; 161(2):224-36. PubMed ID: 23432364
    [Abstract] [Full Text] [Related]

  • 18. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96).
    Isoyama K, Eguchi M, Hibi S, Kinukawa N, Ohkawa H, Kawasaki H, Kosaka Y, Oda T, Oda M, Okamura T, Nishimura S, Hayashi Y, Mori T, Imaizumi M, Mizutani S, Tsukimoto I, Kamada N, Ishii E.
    Br J Haematol; 2002 Sep 28; 118(4):999-1010. PubMed ID: 12199778
    [Abstract] [Full Text] [Related]

  • 19. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
    Nishi M, Eguchi-Ishimae M, Wu Z, Gao W, Iwabuki H, Kawakami S, Tauchi H, Inukai T, Sugita K, Hamasaki Y, Ishii E, Eguchi M.
    Leukemia; 2013 Feb 28; 27(2):389-97. PubMed ID: 22918121
    [Abstract] [Full Text] [Related]

  • 20. Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia.
    Emerenciano M, Barbosa Tda C, de Almeida Lopes B, Meyer C, Marschalek R, Pombo-de-Oliveira MS.
    Br J Haematol; 2015 Jul 28; 170(2):268-71. PubMed ID: 25613690
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.